Zevra Therapeutics (ZVRA) Return on Capital Employed (2015 - 2026)
Zevra Therapeutics (ZVRA) reported Return on Capital Employed of 2.32% for Q1 2026, up 4611.0% on a YoY basis from 0.05% in Q1 2025, and up 91.24% quarter-over-quarter from 26.43% in Q4 2025.
Zevra Therapeutics (ZVRA) Return on Capital Employed (2015 - 2026) Analysis & Trends
Zevra Therapeutics has reported Return on Capital Employed for 12 years, with the latest figure at 2.32% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 4611.0% year-over-year to 2.32%; the trailing twelve-month figure through Mar 2026 stood at 2.32% (up 4611.0% YoY), and the FY2025 full-year result was 32.76%, up 2888.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 2.32%, up from 26.43% in the prior quarter.
- The five-year high for Return on Capital Employed was 0.86% in Q1 2022, with the low at 64.98% in Q3 2024.
- Historically, Return on Capital Employed has averaged 34.22% across 5 years, with a median of 36.98% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 4978 bps — and 2026, when it jumped 4611 bps.
- Zevra Therapeutics' Return on Capital Employed stood at 10.76% in 2022, then plunged by 463 bps to 60.54% in 2023, then gained by 5 bps to 57.7% in 2024, then surged by 54 bps to 26.43% in 2025, then jumped by 91 bps to 2.32% in 2026.
- The last three Return on Capital Employed figures came in at 2.32% (Q1 2026), 26.43% (Q4 2025), and 36.98% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | Zevra Therapeutics | 796.95 Mn | 596.33 Mn | 34.30 Mn | -2.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.32% |
| Dec 31, 2025 | -26.43% |
| Sep 30, 2025 | -36.98% |
| Jun 30, 2025 | -64.16% |
| Mar 31, 2025 | -48.42% |
| Dec 31, 2024 | -57.70% |
| Sep 30, 2024 | -64.98% |
| Jun 30, 2024 | -63.72% |
| Mar 31, 2024 | -43.41% |
| Dec 31, 2023 | -60.54% |
| Mar 31, 2023 | -23.40% |
| Dec 31, 2022 | -10.76% |
| Sep 30, 2022 | -4.01% |
| Jun 30, 2022 | -5.60% |
| Mar 31, 2022 | -0.86% |
| Dec 31, 2021 | 5.91% |
| Sep 30, 2021 | 5.48% |
| Jun 30, 2021 | 7.70% |
| Mar 31, 2021 | 11.00% |
| Dec 31, 2020 | -152.81% |